Q3'25 Survey: What are Psychedelics Investors Excited About? - Psychedelic Alpha breaks down qualitative themes from investor responses

Psychedelics investors' excitement in Psychedelic Alpha's Q3'25 investor survey centers on therapy potential and near-term drug development milestones. A key added driver is the regulatory and legislative landscape. Respondents report interest has risen sharply this year, linked in part to changes in the U.S. administration and more favorable messaging, alongside an uptick in reform proposals by policymakers and regulators in the U.S. and abroad. Within “new and effective therapeutics,” investors cite perceived efficacy, interest in better therapies, and hopes for conditions such as postpartum depression, trauma-related conditions, anxiety disorders, and substance use disorders. Some also point to emerging targets like inflammation, and note the sector has historically been under-invested, which fuels curiosity about additional novel therapies.